Protalix BioTherapeutics ... (PLX)
undefined
undefined%
At close: undefined
1.74
-3.87%
After-hours Dec 13, 2024, 04:17 PM EST

Protalix BioTherapeutics Statistics

Share Statistics

Protalix BioTherapeutics has 73.63M shares outstanding. The number of shares has increased by 0.81% in one year.

Shares Outstanding 73.63M
Shares Change (YoY) n/a
Shares Change (QoQ) 0.31%
Owned by Institutions (%) n/a
Shares Floating 68.06M
Failed to Deliver (FTD) Shares 482
FTD / Avg. Volume 0.16%

Short Selling Information

The latest short interest is 3.10M, so 4.21% of the outstanding shares have been sold short.

Short Interest 3.10M
Short % of Shares Out 4.21%
Short % of Float 4.92%
Short Ratio (days to cover) 22.71

Valuation Ratios

The PE ratio is 14.46 and the forward PE ratio is 2.13. Protalix BioTherapeutics 's PEG ratio is 0.03.

PE Ratio 14.46
Forward PE 2.13
PS Ratio 1.83
Forward PS 1.3
PB Ratio 3.58
P/FCF Ratio -48.71
PEG Ratio 0.03
Financial Ratio History

Enterprise Valuation

Protalix BioTherapeutics Inc. has an Enterprise Value (EV) of 122.82M.

EV / Earnings 14.78
EV / Sales 1.88
EV / EBITDA 10.54
EV / EBIT 11.74
EV / FCF -49.78

Financial Position

The company has a current ratio of 1.54, with a Debt / Equity ratio of 0.65.

Current Ratio 1.54
Quick Ratio 1.12
Debt / Equity 0.65
Total Debt / Capitalization 39.22
Cash Flow / Debt -0.06
Interest Coverage 3.29

Financial Efficiency

Return on equity (ROE) is 0.25% and return on capital (ROIC) is 16.96%.

Return on Equity (ROE) 0.25%
Return on Assets (ROA) 0.1%
Return on Capital (ROIC) 16.96%
Revenue Per Employee 314.88K
Profits Per Employee 39.96K
Employee Count 208
Asset Turnover 0.78
Inventory Turnover 1.21

Taxes

Income Tax 254.00K
Effective Tax Rate 0.03

Stock Price Statistics

The stock price has increased by 5.23% in the last 52 weeks. The beta is 0.67, so Protalix BioTherapeutics 's price volatility has been higher than the market average.

Beta 0.67
52-Week Price Change 5.23%
50-Day Moving Average 1.34
200-Day Moving Average 1.2
Relative Strength Index (RSI) 70.74
Average Volume (20 Days) 294.97K

Income Statement

In the last 12 months, Protalix BioTherapeutics had revenue of $65.49M and earned $8.31M in profits. Earnings per share was $0.12.

Revenue 65.49M
Gross Profit 42.51M
Operating Income 10.46M
Net Income 8.31M
EBITDA 11.65M
EBIT 10.46M
Earnings Per Share (EPS) 0.12
Full Income Statement

Balance Sheet

The company has $23.63M in cash and $26.28M in debt, giving a net cash position of -$2.65M.

Cash & Cash Equivalents 23.63M
Total Debt 26.28M
Net Cash -2.65M
Retained Earnings -381.55M
Total Assets 61.56M
Working Capital 23.63M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$1.32M and capital expenditures -$1.15M, giving a free cash flow of -$2.47M.

Operating Cash Flow -1.32M
Capital Expenditures -1.15M
Free Cash Flow -2.47M
FCF Per Share -0.04
Full Cash Flow Statement

Margins

Gross margin is 64.91%, with operating and profit margins of 15.97% and 12.69%.

Gross Margin 64.91%
Operating Margin 15.97%
Pretax Margin 13.08%
Profit Margin 12.69%
EBITDA Margin 17.79%
EBIT Margin 15.97%
FCF Margin -3.77%

Dividends & Yields

PLX does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield 6.63%
FCF Yield -1.85%
Dividend Details

Analyst Forecast

The average price target for PLX is $10, which is 452.5% higher than the current price. The consensus rating is "Buy".

Price Target $10
Price Target Difference 452.5%
Analyst Consensus Buy
Analyst Count 1
Stock Forecasts

Stock Splits

The last stock split was on Dec 20, 2019. It was a backward split with a ratio of 1:10.

Last Split Date Dec 20, 2019
Split Type backward
Split Ratio 1:10

Scores

Altman Z-Score -5.24
Piotroski F-Score 4